Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study. - Macaluso FS; Fries W; Viola A; Cappello M; Melatti P; Mocciaro F; Scrivo B; Di Caro S; Muscarella S; Ferracane C; Giangreco E; Minissale MG; et al. (Journal of Crohn's & colitis, 2025)